

DAFTAR PUSTAKA

- Abdelhamid, T., Samra, M., Ramadan, H., Mehessin, M., Mokhtar, N. 2011. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: A retrospective study. *Journal of the Egyptian National Cancer Institute* 23, 17-24
- Alamer, F., Alamir, A., Alqahtani, A., Alkabli, A.M., Alshabib, H., Damlaj, M., 2020. Validation of the International Prognostic Index and Subsequent Revision for Diffuse Large B-Cell Lymphoma in Patients From Middle East and North Africa Region. *Cureus* 12(8) : e9620.
- Ali, U., Gibbs, R., Knight, G., & Tsitsikas, D. (2019). Sex-divided reference intervals for mean platelet volume, platelet large cell ratio and plateletcrit using the Sysmex XN-10 automated haematology analyzer in a UK population. *Hematology, Transfusion and Cell Therapy*, 41(2), 153–157.
- Asare, R., Opoku-Okrah, C., Danquah, K.O., Opare-Sem, O., Addai-Mensah, O., Gyamfi, D et al., 2019. Expression of platelet parameters and platelet membrane glycoproteins in childhood Burkitt lymphoma. *Leukemia Research* 84, 106189.
- Budak, Y.U., Polat, M., Huysal, K., 2016. The use of platelet indices, plateletcrit, mean platelet volume and platelet distribution width in emergency non-traumatic abdominal surgery: A systematic review. *Biochemia Medica* 26, 178–193.
- Brown, J.E., Cook, R.J., Lipton, A., Coleman, R.E., 2012. Clinical Cancer Research 18, 6348–6355.
- Catani, M.V., Savini, I., Tullio, V., Gasperi, V., 2020. The “janus face” of platelets in cancer. *International Journal of Molecular Sciences* 21.
- Chen, L.P., Lin, S.J., Yu, M.S., 2012. Prognostic value of platelet count in diffuse large B-cell lymphoma. *Clinical Lymphoma, Myeloma and Leukemia* 12, 32–37.
- Chihara, D., Nastoupil, L.J., Williams, J.N., Lee, P., Koff, J.L., Flowers, C.R., 2015. New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy. *Expert Review of Anticancer Therapy* 15, 531–544.
- Choi, M., Lee, J.O., Jung, J., Lee, J.Y., Lee, E., Lee, H et al., 2019. Prognostic Value of Platelet Count in Patients with Peripheral T Cell Lymphoma. *Acta Haematologica* 141, 176–186.
- Crump, C., Sundquist, K., Sieh, W., Winkleby, M.A., Sundquist, J., 2012. Perinatal and family risk factors for non-hodgkin lymphoma in early life: A swedish national cohort study. *Journal of the National Cancer Institute* 104, 923–930.
- Farhana, A., Lappin, S.L., 2020. Biochemistry, Lactate Dehydrogenase [Internet]. StatPearls Publishing.

- Farmanfarma, K.K., Kiasara, S.H., Hassanipour, S., Salehiniya, H., 2020. Non-Hodgkin ' S Lymphoma in the World: *an Epidemiological Review* 1–6.
- Gou, B., Cao, H., Cheng, X., Shang, W., Xu, M., Qian, W., 2019. Prognostic value of mean platelet volume to plateletcrit ratio in patients with osteosarcoma. *Cancer Management and Research* 11, 1615–1621.
- Gouveia, G.R., Siqueira, S.A.C., Pereira, J., 2012. Pathophysiology and molecular aspects of diffuse large B-cell lymphoma. *Revista Brasileira de Hematologia e Hemoterapia* 34, 447–451.
- Guilherme, R.D.S., Caputto, L.Z., Fonseca, A.L.A., Pereira, J., Fonseca, F.L.A., 2008. Exames laboratoriais complementares indicados no apoio ao diagnóstico do linfoma difuso de grandes células B (LDGCB). *Arquivos Brasileiros de Ciências da Saúde* 33, 185–194.
- Hong, J., Yoon, H.-H., Ahn, H.K., Sym, S.J., Park, J., Park, P.-W., *et al.*, 2013. A retrospective analysis of patients with diffuse large B cell lymphoma. *Acta Haematologica* 130, 305–311.
- Hur, J.Y., Lee, H.Y., Chang, H.J., Choi, C.W., Kim, D.H., Eo, W.K., 2020. Preoperative plateletcrit is a Prognostic Biomarker for Survival in Patients with Non-Small Cell Lung Cancer. *J. Cancer* 11, 2800–2807.
- Kallam, A., Armitage, J., Chen, B., Vose, J. and Bhatt, V., 2016. Center Effect and Socioeconomic Determinants of Overall Survival (OS) of Diffuse Large B Cell Lymphoma (DLBCL). *Blood*, 128(22), pp.5949-5949.
- Kamran, N., Li, Y., Sierra, M., Alghamri, M.S., Kadiyala, P., Appelman, H.D *et al.*, 2018. Melanoma induced immunosuppression is mediated by hematopoietic dysregulation. *OncolImmunology* 7.
- Lehners, N., Krämer, I., Saadati, M., Benner, A., Ho, A. and Witzens-Harig, M., 2017. Analysis of prognostic factors in patients with newly diagnosed diffuse large B-cell lymphoma and skeletal involvement. *BMC Cancer*, 17(1).
- Lenz, G., Wright, G., Dave, S.S., Xiao, W., Powell, J., Zhao, H., *et al.* 2008. Stromal Gene Signatures in Large B-Cell Lymphoma. *New England Journal of Medicine* 359, 2313–2323.
- Li, M., Xia, H., Zheng, H., Li, Y., Liu, J., Hu, L *et al.*, 2019. Red blood cell distribution width and platelet counts are independent prognostic factors and improve the predictive ability of IPI score in diffuse large B-cell lymphoma patients. *BMC Cancer* 19, 1–11.
- Menter, D.G., Tucker, S.C., Kopetz, S., Sood, A.K., Crissman, J.D., Honn, K. V., 2014. Platelets and cancer: A casual or causal relationship: Revisited. *Cancer and Metastasis Reviews* 33, 231–269.
- Middle, S., Coupland, S.E., Taktak, A., Kidgell, V., Slupsky, J.R., Pettitt, A.R., *et al.* 2015. Immunohistochemical analysis indicates that the anatomical location of B cell non Hodgkin lymphoma is determined by differentially expressed chemokine receptors, sphingosine-1-phosphate receptors and integrins. *Experimental Hematology & Oncology* 4, 10.

- Mutlu, H., Artış, T.A., Erden, A., Akca, Z., 2013. Alteration in mean platelet volume and platycrit values in patients with cancer that developed thrombosis. *Clinical and Applied Thrombosis/Hemostasis* 19, 331–333.
- Nogai, H., Dörken, B., Lenz, G., 2011. Pathogenesis of non-Hodgkin's lymphoma. *Journal of Clinical Oncology* 29, 1803–1811.
- Park, J., Yoon, D., Kim, D., Kim, S., Seo, S., Jeong, Y., Lee, S., Park, C., Huh, J. and Suh, C., 2014. The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab. *Annals of Hematology*, 93(10), pp.1755-1764.
- Patti, G., De Caterina, R., Abbate, R., Andreotti, F., Biasucci, L. M., Calabrò, P., *et al.* 2014. Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A 'state-of-the-art' paper. *European Heart Journal*, 35(33), 2213–2223.
- Peng F, Guo L, Yao WK, Zheng Y, Liu Y, Duan XM, Wang YP. 2017. Identification of prognostic factors in patients with diffuse large B-cell lymphoma. *Indian J Pathol Microbiol*, 60, 87-91
- Petrelli, F., Cabiddu, M., Coinu, A., Borgonovo, K., Ghilardi, M., Lonati, V., *et al.* 2015. Prognostic role of lactate dehydrogenase in solid tumors : a systematic review and meta-analysis. *Acta Oncologica* 54, 961–970.
- Qi, J., Gu, C., Wang, W., Xiang, M., Chen, X., Fu, J., 2021. The Addition of Peripheral Blood Inflammatory Indexes to Nomogram Improves the Predictive Accuracy of Survival in Limited-Stage Small Cell Lung Cancer Patients. *Frontiers in Oncology* 11.
- Qian, W., Ge, X.-X., Wu, J., Gong, F.-R., Wu, M.-Y., Xu, M.-D *et al.*, 2019. Prognostic evaluation of resectable colorectal cancer using platelet-associated indicators. *Oncol Lett* 18, 571–580.
- Reksodiputro, A.H., 2015. Multicentre Epidemiology and Survival Study of B Cell Non-Hodgkin Lymphoma Patients In Indonesia. *Journal of Blood Disorders & Transfusion* 06, 2–6.
- Sehn, L.H., Berry, B., Chhanabhai, M., Fitzgerald, C., Gill, K., Hoskins, P., *et al.* 2007. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standart IPI for patients with diffuse large B cell lymphoma treated wiht R-CHOP. *Blood* 109, 1857–1861.
- Shen, Y., Yao, Y., Li, JM., Chen, QS., You, JH., Zhao, HJ *et al.* 2008. Prognostic factors analysis for R-CHOP regimen therapy in diffuse large B cell lymphoma. *Zhonghua Xue Ye Xue Za Zhi*, 29(4):252-7
- Smith, A., Crouch, S., Howell, D., Burton, C., Patmore, R. and Roman, E., 2015. Impact of age and socioeconomic status on treatment and survival from aggressive lymphoma: a UK population-based study of diffuse large B-cell lymphoma. *Cancer Epidemiology*, 39(6), pp.1103-1112.
- Szymańska, K., Park, S., 2018. Non-hodgkin lymphoma: Diagnosis and treatment. *Encyclopedia of Cancer* 3, 44–47.
- Takeuchi, H., Noda, D., Abe, M., Anami, K., Miyawaki, M., Osoegawa, A., *et al.* 2020. Evaluating the Platelet Distribution Width-to-Plateletcrit Ratio as a

- Prognostic Marker for Patients With Breast Cancer. *Anticancer research* 40, 3947–3952.
- Thachil, J., 2015. Platelets in Inflammatory Disorders: A Pathophysiological and Clinical Perspective. *Seminars in Thrombosis and Hemostasis* 41, 572–581.
- Yamamoto, M., Watanabe, K., Fukuda, T., Miura, O., 2017. Prediction for patients with diffuse large B-cell lymphoma refractory to or in first relapse after initial R-CHOP therapy : A single-institution study. *Anticancer Research* 37, 2655–2662.
- Yang, B., Yong, W., Zhu, J., Zheng, W., Zhang, Y., Wang, X., et al. 2005. Clinical characteristics and prognosis of diffuse large B-cell lymphoma. *Zhonghua Zhong Liu Za Zhi*, 27(3):174-6
- Yang, G., Mills, M., Kim, Y., Figura, N.B., Doyle, C., Oliver, D et al., 2019. Enhancement of the Follicular Lymphoma International Prognostic Index (FLIPI) with lymphopenia (FLIPI-L): a predictor for overall survival and histologic transformation. *Blood Cancer Journal* 9.
- Zhang, S., Cui, Y.L., Diao, M.Y., Chen, D.C., Lin, Z.F., 2015. Use of platelet indices for determining illness severity and predicting prognosis in critically ill patients. *Chinese Medical Journal* 128, 2012–2018.
- Zhao, P., Zhu, L., Li, L., Zhou, S., Qiu, L., Qian, Z., et al. 2021. A modified prognostic model in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. *Oncology Letters* 21, 218.
- Zhou, S., Ma, Y., Shi, Y., Tang, L., Zheng, Z., Fang, F et al., 2018. Mean platelet volume predicts prognosis in patients with diffuse large B-cell lymphoma. *Hematological Oncology* 36, 104–109.
- Zhou, Z., Sehn, L.H., Rademaker, A.W., Gordon, L.I., LaCasce, A.S., Crosby-Thompson, A et al., 2014. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. *Blood* 123, 837–842.